| Stephen An, | |
|
3801 Miranda Ave, Palo Alto, CA 94304-1207 | |
| (650) 493-5000 | |
| Not Available |
| Full Name | Stephen An |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 9 Years |
| Location | 3801 Miranda Ave, Palo Alto, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467835991 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | EL6719 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Hospital | San jose, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bay Area Foot Care Inc | 0345329686 | 78 |
News Archive
In a newly published study in Nature Nanotechnology, the shape and geometry of nanoparticles can have a significant impact in modulating adverse injection reactions and offer realistic solutions for patients receiving nanopharmaceuticals—drug delivery systems specializing in microscopic-particle drug combinations.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
A new round of support will help a Purdue University-affiliated startup further develop a platform designed to create drugs for people with hard-to-treat cancers.
A protein involved in multiple cell functions, tumor necrosis factor (TNF) is perhaps best known for provoking destructive inflammation. Recently, drugs blocking the action of TNF have shown promise in the early treatment of rheumatoid arthritis (RA).
› Verified 7 days ago
| Provider Name | Bay Area Foot Care Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1508911892 PECOS PAC ID: 0345329686 Enrollment ID: O20080512000353 |
News Archive
In a newly published study in Nature Nanotechnology, the shape and geometry of nanoparticles can have a significant impact in modulating adverse injection reactions and offer realistic solutions for patients receiving nanopharmaceuticals—drug delivery systems specializing in microscopic-particle drug combinations.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
A new round of support will help a Purdue University-affiliated startup further develop a platform designed to create drugs for people with hard-to-treat cancers.
A protein involved in multiple cell functions, tumor necrosis factor (TNF) is perhaps best known for provoking destructive inflammation. Recently, drugs blocking the action of TNF have shown promise in the early treatment of rheumatoid arthritis (RA).
› Verified 7 days ago
| Provider Name | Cupertino Podiatry Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1942432505 PECOS PAC ID: 0042365306 Enrollment ID: O20090910000221 |
News Archive
In a newly published study in Nature Nanotechnology, the shape and geometry of nanoparticles can have a significant impact in modulating adverse injection reactions and offer realistic solutions for patients receiving nanopharmaceuticals—drug delivery systems specializing in microscopic-particle drug combinations.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
A new round of support will help a Purdue University-affiliated startup further develop a platform designed to create drugs for people with hard-to-treat cancers.
A protein involved in multiple cell functions, tumor necrosis factor (TNF) is perhaps best known for provoking destructive inflammation. Recently, drugs blocking the action of TNF have shown promise in the early treatment of rheumatoid arthritis (RA).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen An, 1565 La Vereda Rd, Berkeley, CA 94708-2035 Ph: () - | Stephen An, 3801 Miranda Ave, Palo Alto, CA 94304-1207 Ph: (650) 493-5000 |
News Archive
In a newly published study in Nature Nanotechnology, the shape and geometry of nanoparticles can have a significant impact in modulating adverse injection reactions and offer realistic solutions for patients receiving nanopharmaceuticals—drug delivery systems specializing in microscopic-particle drug combinations.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
A new round of support will help a Purdue University-affiliated startup further develop a platform designed to create drugs for people with hard-to-treat cancers.
A protein involved in multiple cell functions, tumor necrosis factor (TNF) is perhaps best known for provoking destructive inflammation. Recently, drugs blocking the action of TNF have shown promise in the early treatment of rheumatoid arthritis (RA).
› Verified 7 days ago
Elizabeth Anne Reilly, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Palo Alto, CA 94305 Phone: 650-723-4000 | |
Jonathan Jeah Seun, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Dr. Sandra Jay Loving, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Dr. Eghosa Isa, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-853-2943 | |
Dr. Nancy Vilaysak Kim, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Aaron Z Handa, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Francis Dinh, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 |